Key Points
- Director Amy Duross sold 4,523 shares of BioLife Solutions on Nov. 20 at an average price of $24.51 for about $110,859, and also sold 477 shares on Nov. 19 and 1,000 shares on Nov. 21, leaving her with 25,687 shares (a 14.97% drop in her ownership).
- Shares jumped 9.6% to $26.53 on the latest trading day (volume 540,117 vs. avg. 456,202); the company has a market cap of about $1.28 billion, institutional ownership of 93.24%, and an analyst consensus of "Moderate Buy" with a $31.20 average price target.
BioLife Solutions, Inc. (NASDAQ:BLFS - Get Free Report) Director Amy Duross sold 477 shares of the company's stock in a transaction on Wednesday, November 19th. The shares were sold at an average price of $24.50, for a total transaction of $11,686.50. Following the completion of the sale, the director owned 30,210 shares of the company's stock, valued at approximately $740,145. This represents a 1.55% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.
Amy Duross also recently made the following trade(s):
- On Friday, November 21st, Amy Duross sold 1,000 shares of BioLife Solutions stock. The stock was sold at an average price of $26.00, for a total value of $26,000.00.
- On Thursday, November 20th, Amy Duross sold 4,523 shares of BioLife Solutions stock. The shares were sold at an average price of $24.51, for a total value of $110,858.73.
BioLife Solutions Trading Up 9.6%
Shares of NASDAQ BLFS traded up $2.33 during mid-day trading on Friday, reaching $26.53. 540,117 shares of the company's stock were exchanged, compared to its average volume of 456,202. BioLife Solutions, Inc. has a twelve month low of $19.10 and a twelve month high of $29.62. The firm has a market capitalization of $1.28 billion, a price-to-earnings ratio of -221.06 and a beta of 1.97. The business has a fifty day simple moving average of $26.38 and a 200 day simple moving average of $24.12.
Analyst Upgrades and Downgrades
Several research analysts have recently weighed in on BLFS shares. HC Wainwright reiterated a "buy" rating and issued a $32.00 price target (up previously from $30.00) on shares of BioLife Solutions in a report on Friday, August 8th. Weiss Ratings reiterated a "sell (d-)" rating on shares of BioLife Solutions in a report on Wednesday, October 8th. Zacks Research raised BioLife Solutions from a "hold" rating to a "strong-buy" rating in a research report on Friday, November 7th. Finally, Wall Street Zen raised BioLife Solutions from a "hold" rating to a "buy" rating in a research report on Saturday. One equities research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has given a Sell rating to the company's stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $31.20.
Check Out Our Latest Stock Analysis on BLFS
Institutional Trading of BioLife Solutions
Hedge funds and other institutional investors have recently modified their holdings of the stock. Amalgamated Bank boosted its position in BioLife Solutions by 3.5% during the third quarter. Amalgamated Bank now owns 10,898 shares of the medical equipment provider's stock valued at $278,000 after purchasing an additional 366 shares during the last quarter. Ameritas Investment Partners Inc. boosted its holdings in shares of BioLife Solutions by 12.8% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 3,873 shares of the medical equipment provider's stock valued at $83,000 after buying an additional 441 shares during the last quarter. Louisiana State Employees Retirement System boosted its holdings in shares of BioLife Solutions by 2.9% in the 3rd quarter. Louisiana State Employees Retirement System now owns 17,800 shares of the medical equipment provider's stock valued at $454,000 after buying an additional 500 shares during the last quarter. Isthmus Partners LLC grew its stake in shares of BioLife Solutions by 0.4% in the second quarter. Isthmus Partners LLC now owns 132,125 shares of the medical equipment provider's stock valued at $2,846,000 after buying an additional 509 shares in the last quarter. Finally, Sei Investments Co. increased its holdings in BioLife Solutions by 0.5% during the first quarter. Sei Investments Co. now owns 117,999 shares of the medical equipment provider's stock worth $2,695,000 after buying an additional 547 shares during the last quarter. Institutional investors and hedge funds own 93.24% of the company's stock.
About BioLife Solutions
(
Get Free Report)
BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
